{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:15Z","timestamp":1753891215175,"version":"3.41.2"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Epidermal growth factor receptor (EGFR)-activating mutations are major oncogenic mechanisms in non-small cell lung cancer (NSCLC). Most patients with NSCLC with EGFR mutations benefit from targeted therapy with EGFR- tyrosine kinase inhibitors (TKIs). One of the main limitations of targeted therapy is that the tumor response is not durable, with the inevitable development of drug resistance. Previous studies demonstrated that the potential resistance mechanisms are diverse, including the presence of EGFR T790M, <jats:italic>MET<\/jats:italic> amplification, mesenchymal transformation, and anaplastic lymphoma kinase (<jats:italic>ALK<\/jats:italic>) rearrangement. The patient in our report was diagnosed with stage IA lung adenocarcinoma harboring the EGFR L858R mutation and underwent radical surgery. The patient received icotinib for 12 months after recurrence. Subsequent molecular analysis of the left pleural effusion indicated that <jats:italic>LCLAT1-ALK<\/jats:italic> fusion might be an underlying mechanism contributing to the acquired resistance to icotinib. Ensartinib was prescribed, but the lesion in the right lung continued to progress. Hence, a re-biopsy and molecular analysis of lesions in the right lung was performed to solve this problem. In contrast to the left pleural effusion, EGFR exon 20 T790M might have mediated the acquired resistance in lesions in the right lung of this patient. The combination of osimertinib and ensartinib has achieved a rapid partial response until now. The complexity and heterogeneity in our case may provide new insights into the resistance mechanisms of targeted therapy.<\/jats:p>","DOI":"10.3389\/fmed.2022.906364","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T05:08:38Z","timestamp":1657170518000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Heterogeneity of Resistance Mechanisms in Different Lesions Co-Mediate Acquired Resistance to First-Line Icotinib in EGFR Mutant Non-Small Cell Lung Cancer"],"prefix":"10.3389","volume":"9","author":[{"given":"Zhicong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongxiang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueren","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1200\/JCO.2008.17.7162","article-title":"Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials","volume":"26","author":"Group","year":"2008","journal-title":"J Clin Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"103113","DOI":"10.1016\/j.critrevonc.2020.103113","article-title":"Functional coding\/non-coding variants in EGFR, ROS1 and ALK genes and their role in liquid biopsy as a personalized therapy","volume":"156","author":"Ergoren","year":"2020","journal-title":"Crit Rev Oncol Hematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10555-016-9612-6","article-title":"Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice","volume":"35","author":"Pirker","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.biocel.2016.07.011","article-title":"Management of non-small cell lung cancer in the era of personalized medicine","volume":"78","author":"Rocco","year":"2016","journal-title":"Int J Biochem Cell Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00432-021-03864-4","article-title":"Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations","volume":"148","author":"Han","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1007\/s40487-022-00190-8","article-title":"ADAURA: the splash of osimertinib in adjuvant EGFR-mutant non-small cell lung cancer","volume-title":"Oncol Ther","author":"Ortega-Franco","year":"2022"},{"key":"B8","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3978\/j.issn.2218-6751.2014.08.02","article-title":"Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer","volume":"3","author":"Jiang","year":"2014","journal-title":"Transl Lung Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"6343","DOI":"10.2147\/CMAR.S197337","article-title":"Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors","volume":"11","author":"Xu","year":"2019","journal-title":"Cancer Manag Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/1759-7714.13015","article-title":"Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient","volume":"10","author":"Hu","year":"2019","journal-title":"Thorac Cancer."},{"key":"B15","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/1759-7714.13817","article-title":"ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer","volume":"12","author":"Hou","year":"2021","journal-title":"Thorac Cancer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/cancers9120164","article-title":"Non-canonical thinking for targeting ALK-fusion onco-proteins in lung cancer","volume":"9","author":"Wu","year":"2017","journal-title":"Cancers"},{"key":"B17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12967-021-02982-4","article-title":"Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers","volume":"19","author":"Xia","year":"2021","journal-title":"J Transl Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11523-019-00628-6","article-title":"Clinical management of non-small cell lung cancer with concomitant EGFR mutations and ALK rearrangements: efficacy of EGFR tyrosine kinase inhibitors and crizotinib","volume":"14","author":"Zhao","year":"2019","journal-title":"Target Oncol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.906364\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T05:08:44Z","timestamp":1657170524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.906364\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":18,"alternative-id":["10.3389\/fmed.2022.906364"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.906364","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"article-number":"906364"}}